Maynard Um
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Bernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform
-
-
-
-
-
-
-
Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim
-
-
-
-
-
-
-
Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Bernstein SocGen Group Starts Summit Therapeutics plc (SMMT) at Underperform
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
-
453,615 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

